2 weeks Ago By Defense World Staff
Research analysts at StockNews.com began coverage on shares of Aethlon Medical ( NASDAQ:AEMD – Get Free Report ) in a note issued to investors on Sunday. The firm set a “sell” rating on the medical equipment provider’s stock.
Separately, HC Wainwright reduced their price target on shares of Aethlon Medical from $10.00 to $7.00 and set a “buy” rating on the stock in a research report on Monday, June 24th.
Get Our Latest Research Report on AEMD Aethlon Medical Trading Up 8.0 % Aethlon Medical ( NASDAQ:AEMD – Get Free Report ) last released its quarterly earnings data on Wednesday, August 14th. The medical equipment provider reported ($0.
34) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.10.
During the same period in the previous year, the company earned ($1.30) earnings per share. Sell-side analysts predict that Aethlon Medical will post -1.
1 earnings per share for the current year. Aethlon Medical Company Profile ( Get Free Report ) Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.
Further Reading Five stocks we like better than Aethlon Medical How to Calculate Retirement Income: MarketBeat’s Calculator CarMax’s Impressive Rally: What Investors Should Watch Next How to Invest in Insurance Companies: A Guide MarketBeat Week in Review – 9/23 – 9/27 What is a Bond Market Holiday? How to Invest and Trade Wake Up to This Biotech Stock That Still Has Big Potential Upside Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter ..
